21 results about "Retinal Neuron" patented technology

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention discloses a drug-loaded polymer, an STAT3 inhibitor composite nanoparticle, a preparation method of the STAT3 inhibitor composite nanoparticle and application of the STAT3 inhibitor composite nanoparticle in ophthalmic drugs. The STAT3 inhibitor composite nanoparticle comprises the drug-loaded polymer, an STAT3 inhibitor loaded on the drug-loaded polymer and thermosensitive lipidosome. The drug-loaded polymer is astaxanthin macromolecules, and the astaxanthin macromolecules are prepared by the following steps: in an inert atmosphere, performing condensation polymerization on astaxanthin and HPMDA, and then performing end capping reaction by using mPEG-OH. The compound is used for treating retinal neuron progressive death and ophthalmic diseases caused by axon loss of the retinal neuron progressive death, can show good ROS response and consumption performance, inhibits necrotic apoptosis, apoptosis and pyroptosis of cells, relieves cell death performance, and can show good drug slow release performance.

The invention discloses application of a Foxn3 gene or protein in preparation of a medicine for treating retina ciliary lesion. Experimental results show that Foxn3 is crucial to inhibition of cilia gene expression in non-photosensitive neurons such as bipolar cells and non-long-process cells, neuron functions in retinas of Foxn3 knockout mice are damaged, and deletion of Foxn3 causes ectopic cilia gene expression and abnormal cilia of the non-photosensitive neurons. The invention discloses a promoter directly combined with Foxn3 and inhibiting cilia genes and cilia transcription factors. The promoter comprises Foxj1 and Rfx family members. Foxn3 is used as a key transcription inhibition factor, and a proper cilia structure of the retinal neuron is ensured by preventing non-photosensitive neurons from adopting photosensitive cell-like cilia characteristics. The invention provides a therapeutic target and a drug for retina ciliary lesion.

This document provides methods and compositions for neuroprotection. The neuroprotective composition may be or include cannabinol or a derivative thereof. The neuroprotective composition may be used in the treatment of neurodegenerative diseases. It may be used to protect retinal neurons from degeneration in individuals who require it, such as in the treatment of glaucoma.

A chemical compound including Isopropyl-D-glucopyranoside derivatives and its chemical synthesis to prepare the chemical compound. The Isopropyl-D-glucopyranoside derivatives is used for promoting regeneration of injured brain neurons and retinal neurons.

Provided herein are methods and compositions for neuroprotection. The neuroprotective composition can be or include 4-chlorobutyl-cannabinol (4-chlorobutyl-CBN) or a derivative thereof and / or a pharmaceutically acceptable salt thereof. The neuroprotective composition can be used in the treatment of a neurodegenerative disease. The neuroprotective composition can be used to protect retinal neurons from degeneration in a subject in need thereof, such as for treatment of age-related macular degeneration.

The present invention relates to a composition for preventing and alleviating or treating glaucoma and macular degeneration, containing a Centella asiatica extract. Particularly, the composition increases the glucose metabolism efficiency of cells so as to increase the survival rate of retinal neurons and pigment epithelial cells and protects cells from oxidative damage caused by A2E, thereby being effectively usable as a composition for eye health and for preventing and alleviating or treating glaucoma and macular degeneration.

The present invention relates to a technique capable of treating a retinal neurodegenerative disease through regeneration of a retinal nerve by targeting Prox1 in the mammalian retina using an inhibitor which inhibits Prox1 expression or migration. According to the present invention, inducing the regeneration of the damaged retina in mammals, and thus can be commonly applied to the treatment of various retinal neurodegenerative diseases causing vision loss, and furthermore, when combining with a selective retinal nerve differentiation method or the like, it is expected that the method can be used for the development of an innovative retinal regeneration method capable of selectively regenerating only specific degenerating retinal neurons.

The present disclosure provides inhibitors of one or more subunits of polycomb repressive complex 2 (PRC2) for use in the prevention or the treatment of an eye disorder in a subject in need thereof and methods for treating an eye disorder, e.g. non-cancer disorders, in a subject using a therapeutically effective amount of one or more inhibitors of a subunit of polycomb repressive complex 2 (PRC2).In certain embodiments of the methods of the disclosure, the eye disorders are characterized by degeneration or cell death of retinal neurons.In certain embodiments of the methods of the disclosure, the subunit of PRC2 is EZH1 or EZH2, and the inhibitor is an inhibitor of H3K27 trimethylation.

Provided herein are depolarizing ion channel therapeutics and methods of using the same for boosting retinal neuronal function.

Glucose dendrimers synthesized using hypercore and glucose monosaccharide-based branching units have significantly enhanced accumulation in brain and retina neurons when administered in vivo, compared to dendrimers that do not contain glucose monosaccharide-based branching units, such as PAMAM. Compositions of glucose dendrimers conjugated with one or more therapeutic, prophylactic or diagnostic agents for preventing, treating or diagnosing a disease or disorder in a subject in need thereof, and methods of using the same have been developed. The compositions are particularly suitable for treating and / or ameliorating diseases or disorders associated with diseased neurons in the eye or brain. Methods of treating a human subject having or at risk of having a neurological disease or disorder are provided.

Described herein are compositions and methods for inducing retinal regeneration in a subject. Also described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of, and / or slowing the progression of a retinal degenerative disease, retinal damage, or retinal blindness in a subject. In some embodiments, the compositions and methods may comprise a pharmaceutical composition comprising a Foxp gene expression vector comprising a polynucleotide sequence encoding a Foxp polypeptide, functional variant thereof, or fragment thereof.

Provided herein are depolarizing ion channel therapeutics and a method of boosting retinal neuronal signals in a subject in need thereof without administration of light stimulation or activation by light, the method comprising administering to the subject an effective amount of a depolarizing ion channel therapeutic wherein the depolarizing ion channel therapeutic depolarizes neurons in a neural circuitry of the subject upon administration, and wherein the neurons are downstream of endogenous neural circuitry.

This invention relates to the application of human amniotic epithelial stem cells (hAESCs) in retinal regeneration and repair, belonging to the field of biomedical technology. It aims to address the technical problems of off-target effects, low efficiency, and safety risks associated with existing methods that directly reprogram Müller glial cells (MGs) via viruses. This invention transplants hAESCs into the degenerated subretinal space. hAESCs, through secreting active substances such as matrix metalloproteinases (MMPs), degrade excessively deposited extracellular matrix, improve the pathological microenvironment inhibiting regeneration, and thus promote the reprogramming of endogenous MGs into functional retinal neurons, thereby achieving retinal structural repair and visual function restoration. This invention utilizes highly safe hAESCs and, by remodeling the microenvironment, significantly improves the efficiency and specificity of MG differentiation into functional neurons, providing a new strategy for the treatment of retinal degenerative diseases.

The invention discloses a targeted retina drug-loaded extracellular vesicle as well as a preparation method and application thereof. The targeted retina drug-loaded extracellular vesicle comprises a lactobacillus-derived extracellular vesicle and a retina ischemia-reperfusion injury related disease treatment drug loaded in the extracellular vesicle, the medicine for treating the diseases related to the retinal ischemia reperfusion injury is indolepropionic acid; the loading capacity of the targeted retina drug-loading extracellular vesicle to indolepropionic acid is (6-8) * 10 <-8 > microgram / particle. The drug-loaded extracellular vesicle has the advantages of high drug loading rate, good biocompatibility, good gastrointestinal tract stability, high bioavailability and good safety. Besides, the extracellular vesicles loaded with indolepropionic acid can carry related marker proteins of retinal neurons through a membrane fusion technology, and can reach an eye retina area more efficiently through peripheral vein administration.

The present invention is directed to the use of gold nanoparticles to enable vision in the visually impaired. Retinal neurons remain functional despite photoreceptor degeneration. These neurons can be made light-sensitive to produce action potentials, by gold nanoparticles conjugated to high-avidity ligands for a variety of cellular targets. Once bound to a neuron, these particles transduce millisecond pulses of light into heat, which changes membrane capacitance, depolarizing the cell and eliciting action potentials. The technology described herein along with a camera and decoder can be used to aid the visually impaired by stimulating cells to send the appropriate messages to the visual cortex.

Described herein are compositions and methods for inducing retinal regeneration in a subject. Also described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of, and / or slowing the progression of a retinal degenerative disease, retinal damage, or retinal blindness in a subject. In some embodiments, the compositions and methods may comprise a pharmaceutical composition comprising a Foxp gene expression vector comprising a polynucleotide sequence encoding a Foxp polypeptide, functional variant thereof, or fragment thereof.

The application belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof, wherein the Ber-ApoEVs comprise ApoEVs and Ber carried by the ApoEVs, wherein the ApoEVs are bone marrow mesenchymal stem cell-derived apoptotic vesicles, and the Ber is berberine and derivatives thereof. Researches of the application show that the brand-new Ber-ApoEVs can play a synergistic neuroprotective effect in regulating microglial cell polarization, inflammatory factor release, p38 / MAPK signal, etc., can reduce neural inflammation caused by retinal ischemia-reperfusion (IR), and inhibit retinal neuron apoptosis, and can be used for treating glaucoma.

This invention proposes a stereo temperature measurement method and system based on binocular bionic vision and adaptive enhancement. The method simultaneously acquires original image pairs using binocular infrared cameras and performs bionic preprocessing simulating retinal neuron characteristics to improve brightness adaptability. A multi-scale decomposition tool is used to extract spatial features of the base layer as guiding information, generating an adaptive enhancement coefficient map to perform pixel-level modulation enhancement of the detail layer, reconstructing a high signal-to-noise ratio enhanced infrared image pair. Finally, stereo matching is performed based on the enhanced images to obtain depth information, and a three-dimensional temperature field model is constructed by combining it with a radiation thermometry model. This invention effectively solves the problems of low image contrast and lack of texture in traditional infrared temperature measurement in complex industrial environments, leading to matching difficulties and the impact of distance attenuation on measurement accuracy. It achieves non-contact, adaptive, high-precision three-dimensional stereo temperature measurement.

Retinal disease is responsible for many instances of vision impairment. Often, individuals with vision impaired due to retinal disease continue to have functioning retinal neurons. Thus, systems, methods, and devices to stimulate retinal neurons may restore sight for vision-impaired individuals. Systems, methods, and devices provided herein direct ultrasound energy into retinal neurons and modulate phase and amplitude of ultrasound energy in time and space domains in order to variously stimulate various retinal neurons, generating neural responses consistent with visual reproduction of intended images.

The present invention relates to a retinal ganglion cell death suppressor comprising a BMPR signal transduction inhibitor, a drug comprising a BMPR signal transduction inhibitor for protecting retinal neurons, and a pharmaceutical composition using these for preventing or treating a disease involving retinal ganglion cell death, such as glaucoma, diabetic retinopathy and retinal vascular occlusion.